Correlation between neuromelanin-sensitive MR imaging and 123I-FP-CIT SPECT in patients with parkinsonism

详细信息    查看全文

• 作者：Keita Kuya ; Yuki Shinohara ; Fuminori Miyoshi ; Shinya Fujii ; Yoshio Tanabe…
• 关键词：Neuromelanin ; sensitive MRI ; 123I ; FP ; CIT SPECT ; Parkinsonism ; Specific binding ratio
• 刊名：Neuroradiology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：58
• 期：4
• 页码：351-356
• 全文大小：347 KB
• 参考文献：1.Fearnley JM, Lees AJ (1991) Aging and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301CrossRef PubMed
  2.Ozawa T, Paviour D, Quinn NP, Josephs KA, Sangha H, Kilford L, Healy DG, Wood NW, Lees AJ, Holton JL, Revesz T (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127:2657–2671CrossRef PubMed
  3.Morris H, Wood N, Lees A (1999) Progressive supranuclear palsy (Steele-Richardson-Olszewski disease). Postgrad Med J 75:579–584CrossRef PubMed PubMedCentral
  4.Josephs KA, Tang-Wai DF, Edland SD, Knopman DS, Dickson DW, Parisi JE, Petersen RC, Jack CR Jr, Boeve BF (2004) Correlation between antemortem magnetic resonance imaging findings and pathologically confirmed corticobasal degeneration. Arch Neurol 61:1881–1884PubMed
  5.Graham DG (1979) On the origin and significance of neuromelanin. Arch Pathol Lab Med 103:359–362PubMed
  6.Bazelon M, Fenichel GM, Randall J (1967) Studies on neuromelanin: I. A melanin system in the human adult brainstem. Neurology 17:512–519CrossRef PubMed
  7.Stepień K, Wilczok A, Zajdel A, Dzierzega-Lecznar A, Wilczok T (2000) Peroxynitrite mediated linoleic acid oxidation and tyrosine nitration in the presence of synthetic neuromelanins. Acta Biochim Pol 47:931–940PubMed
  8.Kooncumchoo P, Sharma S, Porter J, Govitrapong P, Ebadi M (2006) Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J Mol Neurosci 28:125–141CrossRef PubMed
  9.Sharma S, Moon CS, Khogali A, Haidous A, Chabenne A, Ojo C, Jelebinkov M, Kurdi Y, Ebadi M (2013) Biomarkers in Parkinson's disease (recent update). Neurochem Int 63:201–229. doi:10.​1016/​j.​neuint.​2013.​06.​005 CrossRef PubMed
  10.Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, Takahashi S, Ehara S, Terayama Y, Sakai A (2006) Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson’s disease. NeuroReport 17:1215–1218CrossRef PubMed
  11.Mann DM, Yates PO (1983) Possible role of neuromelanin in the pathogenesis of Parkinson’s disease. Mech Ageing Dev 21:193–203CrossRef PubMed
  12.Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP (2011) T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson’s disease. Mov Disord 26:1633–1638. doi:10.​1002/​mds.​23722 CrossRef PubMed
  13.Kashihara K, Shinya T, Higaki F (2011) Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson’s disease. J Clin Neurosci 18:1093–1096. doi:10.​1016/​j.​jocn.​2010.​08.​043 CrossRef PubMed
  14.Nikolaus S, Antke C, Kley K, Poeppel TD, Hautzel H, Schmidt D, Müller HW (2007) Investigating the dopaminergic synapse in vivo: I. Molecular imaging studies in humans. Rev Neurosci 18:439–472PubMed
  15.Nikolaus S, Antke C, Muller HW (2009) In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia. Behav Brain Res 204:1–31. doi:10.​1016/​j.​bbr.​2009.​06.​008 CrossRef PubMed
  16.la Fougère C, Pöpperl G, Levin J, Wängler B, Böning G, Uebleis C, Cumming P, Bartenstein P, Bötzel K, Tatsch K (2010) The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med 51:581–587. doi:10.​2967/​jnumed.​109.​071811 CrossRef PubMed
  17.Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, Lang AE (2002) Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 17:303–312CrossRef PubMed
  18.Südmeyer M, Antke C, Zizek T, Beu M, Nikolaus S, Wojtecki L, Schnitzler A, Müller HW (2011) Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach. J Nucl Med 52:733–740. doi:10.​2967/​jnumed.​110.​086959 CrossRef PubMed
  19.Kägi G, Bhatia KP, Tolosa E (2010) The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 81:5–12. doi:10.​1136/​jnnp.​2008.​157370 CrossRef PubMed
  20.Kashihara K, Shinya T, Higaki F (2011) Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. Intern Med 50:1683–1687CrossRef PubMed
  21.Dickson JC, Tossici-Bolt L, Sera T, Erlandsson K, Varrone A, Tatsch K, Hutton BF (2010) The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nucl Med Mol Imaging 37:23–35. doi:10.​1007/​s00259-009-1212-z CrossRef PubMed
  22.Enochs WS, Hyslop WB, Bennett HF, Brown RD 3rd, Koenig SH, Swartz HM (1997) Sources of the increased longitudinal relaxation rates observed in melanotic melanoma: an in vitro study of synthetic melanins. Investig Radiol 24:794–804CrossRef
  23.Enochs WS, Petherick P, Bogdanova A, Mohr U, Weissleder R (1997) Paramagnetic metal scavenging by melanin: MR imaging. Radiology 204:417–423CrossRef PubMed
  24.Ohtsuka C, Sasaki M, Konno K, Kato K, Takahashi J, Yamashita F, Terayama Y (2014) Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord 20:755–760. doi:10.​1016/​j.​parkreldis.​2014.​04.​005 CrossRef PubMed
  25.Kitao S, Matsusue E, Fujii S, Miyoshi F, Kaminou T, Kato S, Ito H, Ogawa T (2013) Correlation between pathology and neuromelanin MR imaging in Parkinson’s disease and dementia with Lewy bodies. Neuroradiology 55:947–953. doi:10.​1007/​s00234-013-1199-9 CrossRef PubMed
  26.Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, Baldwin RM, Fussell B, Smith EO, Charney DS, van Dyck C et al (1995) Decreased single photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 38:589–598CrossRef PubMed
  27.Colloby SJ, McParland S, O'Brien JT, Attems J (2012) Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain 135:2798–2808. doi:10.​1093/​brain/​aws211 CrossRef PubMed
  28.Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ, Jankovic J, McKee A, Brandel JP, Chaudhuri KR, Lai EC, D'Olhaberriague L, Pearce RK, Agid Y (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 55:969–978CrossRef PubMed
  29.Tissingh G, Bergmans P, Booij J, Winogrodzka A, van Royen EA, Stoof JC, Wolters EC (1998) Drug-naive patients with Parkinson’s disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT. J Neurol 245:14–20CrossRef PubMed
  30.Rossi C, Frosini D, Volterrani D, De Feo P, Unti E, Nicoletti V, Kiferle L, Bonuccelli U, Ceravolo R (2010) Differences in nigro-striatal impairment in clinical variants of early Parkinson’s disease: evidence from a FP-CIT SPECT study. Eur J Neurol 17:626–630CrossRef PubMed
  31.Contrafatto D, Mostile G, Nicoletti A, Dibilio V, Raciti L, Lanzafame S, Luca A, Distefano A, Zappia M (2012) [(123) I]FP-CIT-SPECT asymmetry index to differentiate Parkinson’s disease from vascular parkinsonism. Acta Neurol Scand 126:12–16. doi:10.​1111/​j.​1600-0404.​2011.​01583.​x CrossRef PubMed
  32.Zhang J, Zhang Y, Wang J, Cai P, Luo C, Qian Z, Dai Y, Feng H (2010) Characterizing iron deposition in Parkinson’s disease using susceptibility-weighted imaging: an in vivo MR study. Brain Res 1330:124–130. doi:10.​1016/​j.​brainres.​2010.​03.​036 CrossRef PubMed
  33.Baudrexel S, Nürnberger L, Rüb U, Seifried C, Klein JC, Deller T, Steinmetz H, Deichmann R, Hilker R (2010) Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson’s disease. Neuroimage 51:512–520. doi:10.​1016/​j.​neuroimage.​2010.​03.​005 CrossRef PubMed
  34.Barbosa JH, Santos AC, Tumas V, Liu M, Zheng W, Haacke EM, Salmon CE (2015) Quantifying brain iron deposition in patients with Parkinson’s disease using quantitative susceptibility mapping, R2 and R2*. Magn Reson Imaging 33:559–565. doi:10.​1016/​j.​mri.​2015.​02.​021 CrossRef PubMed
  35.Haller S, Badoud S, Nguyen D, Barnaure I, Montandon ML, Lovblad KO, Burkhard PR (2013) Differentiation between Parkinson disease and other forms of Parkinsonism using support vector machine analysis of susceptibility-weighted imaging (SWI): initial results. Eur Radiol 23:12–19. doi:10.​1007/​s00330-012-2579-y CrossRef PubMed
  36.Wang Y, Butros SR, Shuai X, Dai Y, Chen C, Liu M, Haacke EM, Hu J, Xu H (2012) Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol 33:266–273. doi:10.​3174/​ajnr.​A2765 CrossRef PubMed
  37.Ogisu K, Kudo K, Sasaki M, Sakushima K, Yabe I, Sasaki H, Terae S, Nakanishi M, Shirato H (2013) 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson’s disease. Neuroradiology 55:719–724. doi:10.​1007/​s00234-013-1171-8 CrossRef PubMed
  
• 作者单位：Keita Kuya (1)
  Yuki Shinohara (1)
  Fuminori Miyoshi (1)
  Shinya Fujii (1)
  Yoshio Tanabe (1)
  Toshihide Ogawa (1)
  
  1. Division of Radiology, Department of Pathophysiological Therapeutic Science, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago, 683-8504, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Neuroradiology
  Imaging and Radiology
  Neurology
  Neurosurgery
  Neurosciences
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1920

文摘

Introduction Neuromelanin-sensitive MR imaging (MRI) can visualize neuromelanin-containing neurons in the substantia nigra pars compacta (SNc), and its utility has been reported in the evaluation of parkinsonism. Conversely, dopamine transporter imaging by 123I-N-v-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl)nortropane (FP-CIT) SPECT (DaTSCAN) is now an established method for evaluating parkinsonism, detecting presynaptic dopamine neuronal dysfunction. Both methods can assist differentiating neurodegenerative and other forms of parkinsonism. However, to our knowledge, there have been no studies concerning a correlation between the two methods. The aim of this study was to assess the utility of neuromelanin-sensitive MRI for diagnosing parkinsonism by examining a correlation with DaTSCAN.